By Monica Heger

GE Healthcare has purchased genomic services firm SeqWright as a first step in a broader strategy to move its Clarient cancer diagnostic business into next-generation sequencing.

Clarient plans to initially use SeqWright's sequencing capabilities in its collaborations with pharmaceutical companies in clinical trials, but its longer-term plans include the development of sequencing-based cancer diagnostic panels, according to Clarient CEO Carrie Eglinton-Manner.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.